Bio-Rad Laboratories (FRA:BUWA) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
72 GF Score
Price €246.00
GF Value €272.83
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Bio-Rad Laboratories's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:BUWA vs BRKR, MASI, PODD: Margin of Safety % (DCF FCF Based) Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories Margin of Safety % (DCF FCF Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Margin of Safety % (DCF FCF Based) falls into.


FRA:BUWA
72GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued. The current stock price of €246.00 is trading 9.8% below its estimated GF Value™ of €272.83. GuruFocus considers Bio-Rad Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:BUWA:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €272.83 vs. price of €246.00 (9.8% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score

Get the complete analysis for FRA:BUWA

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€246.00
Price
€272.83
GF Value